Continue targeted breast cancer therapy or switch to a new combo
Part of Cancer, Skin clinical trials.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 18 to 75, and have early-stage invasive breast cancer
- Your tumor is HER2-positive (confirmed by pathology testing) and you know your ER and progesterone (PgR) status
- You had neoadjuvant treatment: at least 9 weeks of trastuzumab plus at least 9 weeks of taxane chemotherapy
- After surgery, pathology showed remaining invasive cancer (either >2 cm residual tumor, or lymph node cancer with a large spread)
- You can start the study within 12 weeks after surgery (if no post-op radiation) or within 6 weeks after finishing post-op radiation
- Your body systems meet safety thresholds (bone marrow, liver, kidneys, and a heart scan showing LVEF at least 55%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two HER2-targeted drugs (trastuzumab and pertuzumab) given after surgery for HER2-positive breast cancer. It looks at whether this combination can help reduce the risk of cancer coming back in people who still had some cancer left after neoadjuvant therapy.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.